恶性肿瘤脑转移暨乳腺癌脑转移化疗进展和分子靶向治疗-2009CSCO年会.ppt

总结 临床多学科协作将有助于改善脑转移瘤患者的预后 以替莫唑胺为代表的新型化疗药物在乳腺癌等实体瘤脑转移的治疗中表现出疗效和良好的安全性 以拉帕替尼为代表的分子靶向药物在乳腺癌脑转移的治疗中具有良好前景，值得进一步探讨 * * * * * - This phase ll study evaluated the safety and efficacy of the combination of ERBITUX and FOLFOX-4 as first-line treatment for patients with mCRC. 1. Cervantes A, Casado E, Van Cutsem E et al. Eur J Cancer 2005;Supplement 3:Abstract 642. Updated information presented at ECCO 2005 * * - In this multicenter, open-label, phase II study, patients with metastatic or recurrent CRC received first-line treatment with ERBITUX (400 mg/m2 week 1 and 250 mg/m2 weekly thereafter) plus FOLFOX-4 (every 2 weeks: oxaliplatin 85 mg/m2, day 1; FA 200 mg/m2 2-h infusion and 5-FU 400 mg/m2 i.v. bolus followed by 600 mg/m2 continuous infusion for 22-h, days 1 and 2). - Treatment was continued until disease progression or unacceptable toxicity. 1. Cervantes A, Casado E, Van Cutsem E et al. Eur J Cancer 2005;Supplement 3:Abstract 642. Updated information presented at ECCO 2005 * * - Of the 60 enrolled patients, 46 (77%) were male and the median age was 44.5 years. - The majority of patients were Chinese. - The median Karnofsky performance status was 90%. - The majority of patients (93%) had stage IV disease. Among these patients, 85% had distant metastasis. - The median duration of disease at time of enrolment on the study was 24.2 months. 1. Chan AT, Hsu MM, Goh BC, et al. J Clin Oncol 2005;23:3568-3576 * * - The primary endpoint for the study was the best confirmed overall response. - The secondary endpoints were: -- progression-free survival -- duration of response -- survival time -- safety. 1. Cervantes A, Casado E, Van Cutsem E et al. Eur J Cancer 2005;Supplement 3:Abstract 642. Updated information presented at ECCO 2005 * * * * - Seven patients (12%) had a partial response and a further 29 patients (48%) had stable disease. - Thus, the overall response rate was 12% and the disease control rate was 60%. - The median overall survival was 7.7 months. 1. Chan AT, Hsu M